Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report

Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Daoan, Tang, Shuxian, Li, Dong, Zhao, Weiqing, Wei, Wei, Fang, Cheng, Ji, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374065/
https://www.ncbi.nlm.nih.gov/pubmed/35946524
http://dx.doi.org/10.1097/CAD.0000000000001368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374065/
https://www.ncbi.nlm.nih.gov/pubmed/35946524
http://dx.doi.org/10.1097/CAD.0000000000001368

Ejemplares similares